Report of Foreign Issuer (6-k)
17 August 2020 - 11:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 17, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd,
Denmark, 17 August 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance
with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase
programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 6 August 2020, Novo
Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.
Since the announcement of the programme, the following
transactions have been made:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
6 August 2020
|
115,000
|
402.54
|
46,292,373
|
7 August 2020
|
115,000
|
406.59
|
46,758,374
|
10 August 2020
|
115,000
|
406.94
|
46,798,239
|
11 August 2020
|
115,000
|
415.81
|
47,818,109
|
12 August 2020
|
112,000
|
418.72
|
46,897,030
|
13 August 2020
|
112,000
|
421.18
|
47,172,388
|
14 August 2020
|
110,000
|
416.75
|
45,842,291
|
Accumulated under the programme
|
794,000
|
|
327,578,802
|
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related
to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 14,577 B shares in the period
from 6 August 2020 to 14 August 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme.
Page 2 of 2
With the transactions stated above, Novo Nordisk
owns a total of 20,843,403 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount
of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk
expects to repurchase B shares for an amount up to DKK 17 billion during a 12- month period beginning 5 February 2020. As of
14 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,853,179 B shares at an average share price
of DKK 425.76 per B share equal to a transaction value of DKK 8,878,366,533.
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs
about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook,
Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 50 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 17, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024